BioLine RX

BLRX · TEL

$2.21+$0.2345 (+11.84%)TodayMarket closed · Oct 20, 6:52 PM ET

Prev close $1.98

About BLRX

BioLineRx Ltd. is a clinical stage biopharmaceutical company, which engages in the research and development of treatments that focus on cancer. The company is headquartered in Modiin, Central(Hamerkaz) and currently employs 24 full-time employees. The company went IPO on 2007-01-30. The firm is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The firm is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.

Employees: 24
Headquarters: Modiin, Central(HaMerkaz)
Listed: Jan 30, 2007
Sector: Health Care
Industry: Biotechnology
Website: biolinerx.com

Leadership

BioLine RX executives
Name	Title	Since	Age
Aharon Schwartz	—	2003	80
Philip Serlin	—	—	60
Mali Zeevi	—	—	41
Ella Sorani	—	—	49
Abi Vainstein-Haras	—	—	—
Hillit Mannor Shachar	—	—	—
Michael Anghel	—	—	84
Barbara-Jean Bormann	—	—	59
Raphael Hofstein	—	—	73
Sandra Panem	—	—	76
Nurit Benjamini	—	—	56
Avraham Molcho	—	—	60
Gal Cohen	—	—	—

Similar companies

Companies in the same industry as BioLine RX

PLRZPolyrizon$9.15−5.52%

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.